Cancer Genetics and Epigenetics, 2025, Vol.13, No.2, 50-61 http://medscipublisher.com/index.php/cge 60 Huang X., Li X., Shan W., Chen Y., Zhu Q., and Xia B., 2023, Targeted therapy and immunotherapy: diamonds in the rough in the treatment of epithelial ovarian cancer, Frontiers in Pharmacology, 14: 1131342. https://doi.org/10.3389/fphar.2023.1131342 Jr Bast R.C., 2011, Molecular approaches to personalizing management of ovarian cancer, Annals of Oncolog, 22(Suppl 8): viii5-viii15. https://doi.org/10.1093/annonc/mdr516 Konstantinopoulos P.A., and Matulonis U.A., 2023, Clinical and translational advances in ovarian cancer therapy, Nature Cancer, 4(9): 1239-1257. https://doi.org/10.1038/s43018-023-00617-9 Kuroki L., and Guntupalli S.R., 2020, Treatment of epithelial ovarian cancer, BMJ, 371: m3773. https://doi.org/10.1136/bmj.m3773 Li H.X., and Li J.H., 2024, Gene editing approaches in ovarian cancer current research and future applications, Cancer Genetics and Epigenetics, 12(5): 294-305 https://doi.org/10.5376/cge.2024.12.0028 Lheureux S., Gourley C., Vergote I., and Oza A., 2019, Epithelial ovarian cancer, The Lancet, 393(10177): 1240-1253. https://doi.org/10.1016/S0140-6736(18)32552-2 Liu S., Kasherman L., Fazelzad R., Wang L., Bouchard-Fortier G., Lheureux S., and Krzyzanowska M., 2021, The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: a systematic review and meta-analysis, Gynecologic Oncology, 161(2): 601-612. https://doi.org/10.1016/j.ygyno.2021.01.028 Mok S.C., Bonome T., Vathipadiekal V., Bell A., Johnson M.E., Wong K., Park D.C., Hao K., Yip D., Donninger H., Ozbun L., Samimi G., Brady J., Randonovich M., Pise-Masison C., Barrett J., Wong W., Welch W., Berkowitz R.S., and Birrer M.J., 2009, A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2, Cancer Cell, 16(6): 521-532. https://doi.org/10.1016/j.ccr.2009.10.018 Morand S., Devanaboyina M., Staats H., Stanbery L., and Nemunaitis J., 2021, Ovarian cancer immunotherapy and personalized medicine, International Journal of Molecular Sciences, 22(12): 6532. https://doi.org/10.3390/ijms22126532 Na J.R., Liu Y.Q., Fang K., Tan Y., Liang P., Yan M., Chu J., Gao J., Chen D.S., and Zhang S.X., 2024, Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review, Investigational New Drugs, 42(6): 728-738. https://doi.org/10.1007/s10637-024-01478-4 Nakai H., and Matsumura N., 2022, Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs, International Journal of Clinical Oncology, 27(6): 1001-1012. https://doi.org/10.1007/s10147-022-02163-3 Nick A.M., Coleman R.L., Ramirez P.T., and Sood A.K., 2015, A framework for a personalized surgical approach to ovarian cancer, Nature Reviews Clinical Oncology, 12(4): 239-245. https://doi.org/10.1038/nrclinonc.2015.26 Palaia I., Tomao F., Sassu C.M., Musacchio L., and Panici B., 2020, Immunotherapy for ovarian cancer: recent advances and combination therapeutic approaches, OncoTargets and Therapy, 13: 6109-6129. https://doi.org/10.2147/OTT.S205950 Rojas V., Hirshfield K., Ganesan S., and Rodriguez-Rodriguez L., 2016, Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment, International Journal of Molecular Sciences, 17(12): 2113.. https://doi.org/10.3390/ijms17122113 Schoutrop E., Moyano-Galceran L., Lheureux S., Mattsson J., Lehti K., Dahlstrand H., and Magalhaes I., 2022, Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment, Seminars in Cancer Biology, 86(Pt 3): 207-223. https://doi.org/10.1016/j.semcancer.2022.03.027 Secord A.A., O'Malley D.M., Sood A.K., Westin S.N., and Liu J.F., 2021, Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: a review, Gynecologic Oncology, 162(2): 482-495. https://doi.org/10.1016/j.ygyno.2021.05.018 Singh A., Gupta S., and Sachan M., 2019, Epigenetic biomarkers in the management of ovarian cancer: current prospectives, Frontiers in Cell and Developmental Biology, 7: 182. https://doi.org/10.3389/fcell.2019.00182 Tavares V., Marques I.S., De Melo I.G., Assis J., Pereira D., and Medeiros R., 2024, Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements, International Journal of Molecular Sciences, 25(3): 1845. https://doi.org/10.3390/ijms25031845 Tong A., Di X.J., Zhao X., and Liang X., 2023, Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics, Frontiers in Genetics, 14: 952379. https://doi.org/10.3389/fgene.2023.952379 Tonti N., D’augè G., Cuccu I., De Angelis E., D’Oria O., Perniola G., Laganà A.S., Etrusco A., Ferrari F., Saponara S., Di Donato V., Bogani G., and Giannini A., 2024, The role of tumor biomarkers in tailoring the approach to advanced ovarian cancer, International Journal of Molecular Sciences,25(20): 11239. https://doi.org/10.3390/ijms252011239
RkJQdWJsaXNoZXIy MjQ4ODYzNA==